Literature DB >> 28830577

Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research.

Susan M Irtenkauf1, Susan Sobiechowski1, Laura A Hasselbach1, Kevin K Nelson1, Andrea D Transou1, Enoch T Carlton1, Tom Mikkelsen1, Ana C deCarvalho2.   

Abstract

Glioblastoma is an aggressive primary brain tumor predominantly localized to the cerebral cortex. We developed a panel of patient-derived mouse orthotopic xenografts (PDOX) for preclinical drug studies by implanting cancer stem cells (CSC) cultured from fresh surgical specimens intracranially into 8-wk-old female athymic nude mice. Here we optimize the glioblastoma PDOX model by assessing the effect of implantation location on tumor growth, survival, and histologic characteristics. To trace the distribution of intracranial injections, toluidine blue dye was injected at 4 locations with defined mediolateral, anterioposterior, and dorsoventral coordinates within the cerebral cortex. Glioblastoma CSC from 4 patients and a glioblastoma nonstem-cell line were then implanted by using the same coordinates for evaluation of tumor location, growth rate, and morphologic and histologic features. Dye injections into one of the defined locations resulted in dye dissemination throughout the ventricles, whereas tumor cell implantation at the same location resulted in a much higher percentage of small multifocal ventricular tumors than did the other 3 locations tested. Ventricular tumors were associated with a lower tumor growth rate, as measured by in vivo bioluminescence imaging, and decreased survival in 4 of 5 cell lines. In addition, tissue oxygenation, vasculature, and the expression of astrocytic markers were altered in ventricular tumors compared with nonventricular tumors. Based on this information, we identified an optimal implantation location that avoided the ventricles and favored cortical tumor growth. To assess the effects of stress from oral drug administration, mice that underwent daily gavage were compared with stress-positive and -negative control groups. Oral gavage procedures did not significantly affect the survival of the implanted mice or physiologic measurements of stress. Our findings document the importance of optimization of the implantation site for preclinical mouse models of glioblastoma.

Entities:  

Mesh:

Year:  2017        PMID: 28830577      PMCID: PMC5557202     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  43 in total

1.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

Review 2.  Brain tumour stem cells.

Authors:  Angelo L Vescovi; Rossella Galli; Brent A Reynolds
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

Review 3.  New cast for a new era: preclinical cancer drug development revisited.

Authors:  Grit S Herter-Sprie; Andrew L Kung; Kwok-Kin Wong
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

4.  Heterotransplantation of a human malignant tumour to "Nude" mice.

Authors:  J Rygaard; C O Povlsen
Journal:  Acta Pathol Microbiol Scand       Date:  1969

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 6.  Impact of stress on cancer metastasis.

Authors:  Myrthala Moreno-Smith; Susan K Lutgendorf; Anil K Sood
Journal:  Future Oncol       Date:  2010-12       Impact factor: 3.404

7.  Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.

Authors:  Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

Review 8.  Intraventricular Glioblastomas.

Authors:  Atef Ben Nsir; Yassine Gdoura; Quoc-Anh Thai; Alia Zhani Kassar; Nejib Hattab; Hafedh Jemel
Journal:  World Neurosurg       Date:  2016-01-08       Impact factor: 2.104

9.  Prognosis of patients with multifocal glioblastoma: a case-control study.

Authors:  Chirag G Patil; Anthony Yi; Adam Elramsisy; Jethro Hu; Debraj Mukherjee; Dwain K Irvin; John S Yu; Serguei I Bannykh; Keith L Black; Miriam Nuño
Journal:  J Neurosurg       Date:  2012-08-24       Impact factor: 5.115

10.  Effects of chronic restraint stress on body weight, food intake, and hypothalamic gene expressions in mice.

Authors:  Joo Yeon Jeong; Dong Hoon Lee; Sang Soo Kang
Journal:  Endocrinol Metab (Seoul)       Date:  2013-12-12
View more
  13 in total

1.  Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.

Authors:  Derek Reichel; Bien Sagong; James Teh; Yi Zhang; Shawn Wagner; Hongqiang Wang; Leland W K Chung; Pramod Butte; Keith L Black; John S Yu; J Manuel Perez
Journal:  ACS Nano       Date:  2020-06-23       Impact factor: 15.881

Review 2.  Role of endolysosomes and inter-organellar signaling in brain disease.

Authors:  Zahra Afghah; Xuesong Chen; Jonathan D Geiger
Journal:  Neurobiol Dis       Date:  2019-11-09       Impact factor: 5.996

3.  RNF216 Alleviates Radiation-Induced Apoptosis and DNA Damage Through Regulating Ubiquitination-Mediated Degradation of p53 in Glioblastoma.

Authors:  Songwang Xie; Zhen Hong; Yan Li; Junyong Wang; Jian Wang; Shaoquan Li; Yongchang Liu
Journal:  Mol Neurobiol       Date:  2022-05-20       Impact factor: 5.682

Review 4.  Necrotic reshaping of the glioma microenvironment drives disease progression.

Authors:  Steven M Markwell; James L Ross; Cheryl L Olson; Daniel J Brat
Journal:  Acta Neuropathol       Date:  2022-01-17       Impact factor: 15.887

5.  The impact of initial tumor microenvironment on imaging phenotype.

Authors:  Tavarekere N Nagaraja; Ana C deCarvalho; Stephen L Brown; Brent Griffith; Katelynn Farmer; Susan Irtenkauf; Laura Hasselbach; Abir Mukherjee; Seamus Bartlett; O Grahm Valadie; Glauber Cabral; Robert A Knight; Ian Y Lee; George W Divine; James R Ewing
Journal:  Cancer Treat Res Commun       Date:  2021-01-19

6.  Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma.

Authors:  Ana C deCarvalho; Hoon Kim; Laila M Poisson; Mary E Winn; Claudius Mueller; David Cherba; Julie Koeman; Sahil Seth; Alexei Protopopov; Michelle Felicella; Siyuan Zheng; Asha Multani; Yongying Jiang; Jianhua Zhang; Do-Hyun Nam; Emanuel F Petricoin; Lynda Chin; Tom Mikkelsen; Roel G W Verhaak
Journal:  Nat Genet       Date:  2018-04-23       Impact factor: 38.330

Review 7.  Patient-Derived Cancer Organoids for Precision Oncology Treatment.

Authors:  Mark N Pernik; Cylaina E Bird; Jeffrey I Traylor; Diana D Shi; Timothy E Richardson; Samuel K McBrayer; Kalil G Abdullah
Journal:  J Pers Med       Date:  2021-05-17

Review 8.  Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail.

Authors:  Zachariah P Tritz; Katayoun Ayasoufi; Aaron J Johnson
Journal:  Neurooncol Adv       Date:  2021-05-14

9.  Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas.

Authors:  Wenxin Zeng; Zhaohua Tang; Yongguo Li; Guangnian Yin; Zili Liu; Jie Gao; Yan Chen; Feilan Chen
Journal:  Cancer Cell Int       Date:  2020-01-03       Impact factor: 5.722

Review 10.  Contemporary Mouse Models in Glioma Research.

Authors:  William H Hicks; Cylaina E Bird; Jeffrey I Traylor; Diana D Shi; Tarek Y El Ahmadieh; Timothy E Richardson; Samuel K McBrayer; Kalil G Abdullah
Journal:  Cells       Date:  2021-03-23       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.